Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye?
The role of iron chelation therapy in myelodysplastic syndrome (MDS) remains controversial. Averting cardiac dysfunction in low-grade MDS patients who have sufficient longevity to experience deleterious cardiac effects of iron overload has been the major argument in favor of iron chelation. Although there is significant evidence showing the adverse impact of transfusion dependency on survival in MDS, direct evidence linking tissue iron overload to poor survival or in particular to cardiac dysfunction is lacking. Given the heterogeneity of MDS, it is likely that the pathophysiology of iron overload is equally heterogeneous and complex in these patients. In this article, I argue that prevention of cardiac dysfunction in patients with lower grades of MDS may not be the major benefit of iron chelation therapy, and present evidence suggesting a potential benefit of iron chelation on 3 other outcomes, namely (1) lowering infection risk, (2) improving the outcome of allogeneic hematopoietic stem cell transplantation, and (3) delaying leukemic transformation. These outcomes have particular relevance for patients with higher grades of MDS and should be evaluated in future prospective clinical trials that include patients with all grades of MDS to fully evaluate the benefit of iron chelation therapy.
Pullarkat
Vinod
V
Division of Hematology and Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, CA, USA. vpullarkat@coh.org
D000818:Animals; D015913:Chelation Therapy; D002986:Clinical Trials as Topic; D006801:Humans; D007501:Iron; D007502:Iron Chelating Agents / Q000627:therapeutic use*; D019190:Iron Overload / Q000209:etiology / Q000517:prevention & control*; D009190:Myelodysplastic Syndromes / Q000150:complications / Q000188:drug therapy*
D007502:Iron Chelating Agents; D007501:Iron